Eli Lilly的Verzenio显示,在用于乳腺癌标准治疗时,可以提供大量生存福利。 Eli Lilly's Verzenio shows significant survival benefits when used with standard breast cancer treatments.

Eli Lilly的乳癌药物Verzenio显示,与标准激素疗法同时在高危、早期乳腺癌患者身上使用两年后,总体存活率有了显著改善。 Eli Lilly's breast cancer drug, Verzenio, has shown significant improvement in overall survival when used alongside standard hormone therapy for two years in high-risk, early-stage breast cancer patients. 在包括超过5,600名患者的第三期试验monarchE中,在预防复发和远期复发方面显示出持续的益处. The Phase 3 trial, monarchE, which included over 5,600 patients, demonstrated a sustained benefit in preventing recurrence and distant relapse. 这些调查结果可以将Verzenio确定为符合资格的病人的标准治疗方法。 These findings could establish Verzenio as a standard treatment for eligible patients.